Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Do you support it?
Want to know if it passes?
We'll email you when HR 6033 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 6033.
You're tracking HR 6033
We'll email you the moment it moves.
HR 6033 — Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Last action — Referred to the House Committee on Energy and Commerce.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
Bill Text
We don't have the full text on file for this bill yet.
Read HR 6033 on the official United States source →Action History
-
Referred to the House Committee on Energy and Commerce.
-
Introduced in House
Sponsors
- Scott Peters · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 6033 do?
- Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
- Who sponsors HR 6033?
- HR 6033 is sponsored by Scott Peters (D).
- What is the current status of HR 6033?
- This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 6033?
- Track HR 6033 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 6033
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 6033
Last checked for changes about 14 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →